Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher, Mike F. Burbridge
Current Oncology Reports (2017) Vol. 19, Iss. 3
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

YAP/TAZ upstream signals and downstream responses
Antonio Totaro, Tito Panciera, Stefano Piccolo
Nature Cell Biology (2018) Vol. 20, Iss. 8, pp. 888-899
Open Access | Times Cited: 824
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu, Yuquan Wei, Xiawei Wei
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 393
How macrophages deal with death
Greg Lemke
Nature reviews. Immunology (2019) Vol. 19, Iss. 9, pp. 539-549
Open Access | Times Cited: 336
An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance
Assaf C. Bester, Jonathan D. Lee, Alejandro Chavez, et al.
Cell (2018) Vol. 173, Iss. 3, pp. 649-664.e20
Open Access | Times Cited: 276
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose, Bruce Robinson, Steven I. Sherman, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 8, pp. 1126-1138
Closed Access | Times Cited: 181
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
Wenfeng Hua, Yuan Zhao, Xiaohan Jin, et al.
Gynecologic Oncology (2018) Vol. 151, Iss. 2, pp. 356-365
Closed Access | Times Cited: 164
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Shujing Wang, Jingrui Wang, Zhiqiang Chen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 148
Stromal changes in the aged lung induce an emergence from melanoma dormancy
Mitchell E. Fane, Yash Chhabra, Gretchen M. Alicea, et al.
Nature (2022) Vol. 606, Iss. 7913, pp. 396-405
Open Access | Times Cited: 114
Advances in Lung Cancer Treatment Using Nanomedicines
Akshansh Sharma, Devanshi Shambhwani, Sadanand Pandey, et al.
ACS Omega (2022) Vol. 8, Iss. 1, pp. 10-41
Open Access | Times Cited: 103
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Aging, inflammation and cancer
Barbara Bottazzi, Elio Ríboli, Alberto Mantovani
Seminars in Immunology (2018) Vol. 40, pp. 74-82
Closed Access | Times Cited: 137
The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
Monica Fedele, Laura Cerchia, Gennaro Chiappetta
Cancers (2017) Vol. 9, Iss. 10, pp. 134-134
Open Access | Times Cited: 130
Innate immunity, inflammation and tumour progression: double‐edged swords
Alberto Mantovani, Andrea Ponzetta, Antonio Inforzato, et al.
Journal of Internal Medicine (2019) Vol. 285, Iss. 5, pp. 524-532
Open Access | Times Cited: 81
Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
Michael J. Fisher, Chie‐Schin Shih, Steven D. Rhodes, et al.
Nature Medicine (2021) Vol. 27, Iss. 1, pp. 165-173
Open Access | Times Cited: 68
Resolving inflammation by TAM receptor activation
Juliana P. Vago, Flávio A. Amaral, Fons A. J. van de Loo
Pharmacology & Therapeutics (2021) Vol. 227, pp. 107893-107893
Open Access | Times Cited: 62
The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Raefa Abou Khouzam, Rania F. Zaarour, Klaudia Brodaczewska, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Solange Peters, Luis Paz‐Ares, Roy S. Herbst, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004863-e004863
Open Access | Times Cited: 43
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam‐Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, et al.
Science Advances (2022) Vol. 8, Iss. 20
Open Access | Times Cited: 40
Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management
Dong‐Oh Moon
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2911-2911
Open Access | Times Cited: 11
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
Pierre‐Yves Dumas, Cécile Naudin, Severine Martin‐Lannerée, et al.
Haematologica (2019) Vol. 104, Iss. 10, pp. 2017-2027
Open Access | Times Cited: 71
Axl inhibitors as novel cancer therapeutic agents
Yingying Shen, Xiguang Chen, Jun He, et al.
Life Sciences (2018) Vol. 198, pp. 99-111
Closed Access | Times Cited: 66
Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis
Ashwaq Hamid Salem Yehya, Muhammad Asif, Sven Petersen, et al.
Medicina (2018) Vol. 54, Iss. 1, pp. 8-8
Open Access | Times Cited: 66
MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation
Chihiro Nishi, Yuichi Yanagihashi, Katsumori Segawa, et al.
Journal of Biological Chemistry (2019) Vol. 294, Iss. 18, pp. 7221-7230
Open Access | Times Cited: 56
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Stéphane Terry, Cécile Dalban, Nathalie Rioux‐Leclercq, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 24, pp. 6749-6760
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top